Ignite Creation Date:
2024-05-05 @ 7:40 PM
Last Modification Date:
2024-10-26 @ 9:52 AM
Study NCT ID:
NCT00718536
Status:
COMPLETED
Last Update Posted:
2019-12-05
First Post:
2008-07-16
Brief Title:
Clinical Trial Assessing Once Daily Raltegravir Administration 800 mg QD in HIV-1-Infected Patients Receiving Unboosted Atazanavir 400 mg QD- Based Antiretroviral Therapy
Sponsor:
Organization:
Germans Trias i Pujol Hospital
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
15
Enrollment Type:
ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE4 |
Observational Models:
Time Perspective List:
Who Masked List: